Q1 FY27: Revenue up 21.9% to Rs 422 Cr, PAT rises 30.1% YoY

Revenue Growth 20pctPat Growth 25pctEbitda Margin ExpansionResults View source PDF Explain this filing

CORONA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.7%Reaction day

₹2100.00

prior close

₹2210.00

announcement price

After-mkt

timing

Nifty Microcap 250market+1.3%-0.6% vs market

Pharmaceuticals peers, median of 163sector+1.0%-0.2% vs sector

On the reaction day the stock moved 0.6 pts less than Nifty Microcap 250 and 0.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-3.6

10m

-4.4

15m

-5.2

30m

-6.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.7+1.3-0.6+1.0-0.2

Next day

+2.5+1.8+0.7+0.7+1.8

+0.0+3.1-3.1+0.3-0.3

-2.8+3.5-6.3+0.7-3.5

-2.4+3.5-5.9+1.5-3.9

-1.0+3.4-4.5+1.3-2.4

+1.3+3.6-2.3+1.6-0.3

15d

+2.1+4.9-2.8+0.8+1.2

+1.7+4.4-2.7+1.6+0.1

-3.3+2.9-6.2+1.9-5.2

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 163Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Corona Remedies Q1FY27 revenue rose 21.9% YoY to Rs 422.4 Cr from Rs 346.5 Cr. PAT grew 30.1% to Rs 60.1 Cr from Rs 46.2 Cr. EBITDA up 33.5% at Rs 93.1 Cr with margin expanding 190 bps to 22%. PAT margin rose 90 bps to 14.2%. EPS at Rs 9.83 versus Rs 7.59. Company moved up 3 ranks to 26th in IPM and inaugurated a new EU-GMP Female Hormone plant in Ahmedabad.

Likely market impact

Strong Q1 with double-digit revenue and profit growth, expanding margins, and improving market rank signal positive momentum for shareholders.